

RECEIVED
CENTRAL FAX CENTER

DEC 14 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Shcherbakova et al.

Application No. 10/531,161

Filed: April 12, 2005

For: QUINAZOLINONE COMPOUNDS AS
CALCILYTICS

Group Art Unit: 1614

Examiner: Tamthom Ngo Truong

Attorney Docket No. 50821/5

Date: December 14, 2006

Confirmation No. 4723

BEST AVAILABLE COPY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

TO THE COMMISSIONER FOR PATENTS:

1. Pursuant to the duty of disclosure, documents listed on the accompanying Form PTO-1449 (or equivalent) are presented for the Examiner's consideration.
 - ☒ Copies of listed U.S. patents and U.S. patent application publications are not required for submission. (37 C.F.R. § 1.98(a)(2)(ii))
 - ☒ Copies of listed foreign patent documents and/or non-patent literature are enclosed. (37 C.F.R. § 1.98(a)(2))
 - ☐ Copies of the documents listed at (sheet/cite no.) _____ of the attached Form PTO-1449 (or equivalent) are omitted because (1) they are already of record in U.S. Patent Application No. _____, filed _____, on which this application relies for an earlier filing date under 35 U.S.C. § 120; and (2) any information disclosure statement filed in the prosecution of Application No. _____, complies with 37 CFR §§ 1.98(a) through (c). (37 C.F.R. § 1.98(d))
 - ☐ A copy of copending U.S. Patent Application No. _____, filed _____, for _____, listed at (sheet/cite no.) _____ of the attached Form PTO-1449 (or equivalent), ☐ is enclosed / ☐ is omitted. (Copy not required if available via IFW. 1287 OG 163 (Oct. 19, 2004).)
2. This information disclosure statement is being submitted (check box a., b., or c.):
 - a. ☐ Within three months of the filing date of a national application or entry of the national stage in an international application; or before the mailing of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114. (No statement under 37 CFR 1.97(e) is required.); or

RECEIVED
CENTRAL FAX CENTER

DEC 14 2006

BEST AVAILABLE COPY

- b. ☒ After the period set forth in paragraph 2a, but before the mailing date of either a final action, a notice of allowance, or an action that otherwise closes prosecution in the application. (Check box i. or ii.)
- i. ☒ The \$180.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is paid herewith, or
- ii. ☐ A statement specified by 37 CFR 1.97(e) is set forth below; or
- c. ☐ After the mailing date of a final action or notice of allowance and on or before payment of the issue fee. A statement specified by 37 CFR 1.97(e) is set forth below. Enclosed is the \$180.00 information disclosure statement processing fee set forth in 37 CFR 1.17(p).

3. Fee Payment

- a. ☒ Payment by credit card. Form PTO-2038 is attached.
- b. ☐ Please charge our Deposit Account No. 502375 in the amount of \$_____.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with filing of these papers, or credit overpayment to Deposit Account No. 502375.

4. If a statement specified by 37 CFR 1.97(e) is required, the attorney or agent signing below hereby states that:

- ☐ each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- ☐ no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.

5. ☐ A concise explanation of the relevance of each document not in the English language and/or selected documents in the English language is set forth below.

Respectfully submitted,

NPS Pharmaceuticals, Inc.

By


Kevin B. Laurence
Registration No. 38,219

STOEL RIVES LLP
One Utah Center Suite 1100
201 S Main Street
Salt Lake City, UT 84111-4904
Telephone: (801) 328-3131
Facsimile: (801) 578-6999

BEST AVAILABLE COPY

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

50821/5

Application Number

10/531,161

Applicant(s)

Shcherbakova et al.

Filing Date

April 12, 2005

Group Art Unit

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	6,413,973	07/02/2002	Walter et al.	514	259	11/27/1998

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	US 2005/0085493	04/21/2005	Brain et al.	514	266.2	02/05/2003
	2.	US 2006/0154942	07/13/2006	Culshaw et al.	514	266.24	10/10/2003
	3.	US 2004/0180912	09/16/2004	Beerli et al.	514	266.31	06/14/2002
	4.	US 2006/0079685	04/13/2006	Altman et al.	544	283	12/22/2003

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	1.	Declaration of Will Heaton dated December 13, 2006.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY